Brief: Acorda Therapeutics Reports Q4 2020 Financial Results
04/03/2021 21:35
March 4 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* Q4 NON-GAAP LOSS PER SHARE $2.50
* Q4 GAAP LOSS PER SHARE $9.82
* SEES FY 2021 REVENUE $75 MILLION TO $85 MILLION
* TOTAL 2021 NON-GAAP OPERATING EXPENSE EXPECTED TO BE
$130-$140
MILLION
* QTRLY TOTAL REVENUE $38.2 MILLION VERSUS $50.5 MILLION
Source text for Eikon: ID:nBw272VlWa
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease